

Q4FY23 result review
and TP change

Defence

Target price: Rs140

Target price revision
Rs140 from Rs125

Shareholding pattern

	Sep '22	Dec '22	Mar '23
Promoters	51.1	51.1	51.1
Institutional investors	42.3	42.5	42.0
MFs and others	21.2	20.6	20.1
Fls/Insurance	3.6	4.4	5.3
FII	17.5	17.5	16.6
Others	6.6	6.4	6.9

Source: BSE India

ESG disclosure score

Year	2021	2022	Chg
ESG score	35.6	36.2	0.6
Environment	17.6	17.6	0.0
Social	25.5	27.4	1.8
Governance	63.6	63.6	0.0

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: Bloomberg, I-sec research

Research Analysts:

Amit Dixit

amit.dixit@icicisecurities.com
+91 22 6807 7289

Mohit Lohia

mohit.lohia@icicisecurities.com
+91 22 6807 7510

Pritish Urumkar

Pritish.urumkar@icicisecurities.com
+91 22 6807 7314

INDIA

Bharat Electronics

BUY

Maintained

Rs109

Bharat Electronics' (BEL) Q4FY23 performance was ahead of street estimates on all counts. In FY23, management met its guidance for order inflow of Rs205bn, revenue growth of 15% and EBITDA margin of 21-23%. Key points: 1) EBITDA at Rs18.3bn (up 16% YoY) was 8% ahead of street estimates; 2) orderbook at Rs607bn implies bill-to-book ratio of 3.5x; 3) EBITDA margin rose to 28% in Q4FY23 (FY23: 23%); 4) receivable days were stable YoY at 148; cash & equivalents were at Rs3.9bn vs Rs1.3bn in FY22; and 5) cash dividend of Rs1.2/share thus far for FY23, besides, bonus share issue of 2:1 in Sep-22.

Going ahead, management has guided for order inflow of Rs200bn, revenue growth of 17% YoY and EBITDA margin of 21-23% (incl. other income) for FY24. We introduce FY25E numbers at this stage and expect 12.6% EPS (FY23-FY25E) CAGR. In our view, with its finger in the pie in almost all the upcoming orders over the next few years, BEL is the best play in the defence space. We roll-over the valuation to FY25E and maintain BUY rating on the stock with a revised TP of Rs140 (earlier Rs125) on an unchanged 25x FY25E EPS.

► **Performance ahead of estimates; orderbook concerns allayed.** BEL's Q4FY23 performance was ahead of street's estimates and achieved management's guidance for FY23. Key points: 1) Orderbook has risen to the highest-ever level of Rs607bn, implying bill-to-book ratio of 3.5x (ttm); 2) EBITDA margin rose to 28% owing to raw material sourcing efficiencies and higher value of production (VoP)/material cost ratio; 3) other expenses during the quarter rose 46% YoY to Rs7.3bn owing to liquidated damages (LD) charge of Rs3.6bn; 4) working capital for FY23 remained firmly in control with receivable days unchanged YoY at 148 and higher cash balance at Rs3.9bn; and 4) Board recommended second interim dividend of Rs0.6/share. Going ahead, management expects growth momentum to sustain with EBITDA margin at 21-23% and revenue growth of 17% YoY in FY24.

► **Significant opportunities for orderbook accretion.** During Q4FY24 earnings call, the management guided for an order inflow of Rs200bn in FY24, comprising: 1) Rs40bn from Akash 3rd and 4th regiment orders; 2) Rs45bn from long term fuse requirement contract; 3) Rs50-60bn from the recently issued orders of naval platforms; and 4) Rs10bn from Shakti EW system for Indian Navy. In addition, we believe MRSAM, QRSAM and ATGM orders in medium term could add another Rs200bn. In the longer term, we believe orders from Tejas Mk1A and Mk2 as well as next-generation corvettes are likely to keep orderbook robust. In our view, BEL is significantly immune to potential delays or lower spending as it has exposure to most major upcoming orders. Hence, the current bill to book ratio of 3.5x is comforting. Besides, improving indigenisation and fast developing ecosystem for its products imply margins are likely to improve and working capital cycle is expected to remain in check.

Market Cap	Rs795bn/US\$9.6bn
Reuters/Bloomberg	BAJE.BO/BHE IN
Shares Outstanding (mn)	7,309.8
52-week Range (Rs)	113/75
Free Float (%)	48.9
FII (%)	16.6
Daily Volume (US\$/'000)	17,651
Absolute Return 3m (%)	14.9
Absolute Return 12m (%)	43.5
Sensex Return 3m (%)	4.2
Sensex Return 12m (%)	15.9

Year to March	FY22	FY23	FY24E	FY25E
Revenue (Rs mn)	1,53,682	1,77,344	2,07,365	2,42,406
Net Income (Rs mn)	24,002	29,862	33,705	40,755
Dil. EPS (Rs)	3.3	1.4	4.6	5.6
% Chg YoY	14.3	(58.5)	238.6	20.9
P/E (x)	33.2	80.0	23.6	19.6
CEPS (Rs)	3.8	1.6	5.3	6.3
EV/E (x)	20.9	55.9	14.9	12.2
Dividend Yield (%)	-	-	3.7	3.7
RoCE (%)	25.7	21.2	23.6	27.0
RoE (%)	19.5	21.5	23.6	26.4

► **Outlook and valuation: Robust potential-** We believe BEL is set to gain both from steady execution and orderbook accretion. We maintain **BUY** on BEL stock with a revised TP of Rs140/share (earlier Rs125) on 25x FY25E EPS. Slower-than-expected orderbook build up is the key risk to our thesis.

Table 1: Q4FY23 result review (standalone)

(Rs mn)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	% Chg YoY	% Chg QoQ
Net Sales	36,937	63,249	31,128	39,458	41,310	64,566	2.1	56.3
Other Operating income	379	1,242	492	496	849	1,291	3.9	52.1
Sales Ex Other Op income	36,558	62,007	30,636	38,962	40,461	63,275	2.0	56.4
Gross Margin	14,935	26,439	13,043	17,076	17,153	31,101	17.6	81.3
Gross Margin (%)	40.4	41.8	41.9	43.3	41.5	48.2		
Gross Margin ex Other Op Income	14,556	25,196	12,551	16,580	16,304	29,810	18.3	82.8
Gross Margin ex Other Op Income (%)	39.8	40.6	41.0	42.6	40.3	47.1		
Employee Costs	5,039	5,778	5,764	5,955	5,674	5,584	(3.3)	(1.6)
EBITDA	8,221	15,678	5,135	8,558	8,535	18,248	16.4	113.8
EBITDA Margin (%) on net sales	22.3	24.8	16.5	21.7	20.7	28.3		
EBITDA Ex Other Op Income	7,842	14,436	4,643	8,062	7,686	16,957	17.5	120.6
EBITDA Ex Other Op Income (%)	21.5	23.3	15.2	20.7	19.0	26.8		
PAT	5,834	11,418	4,315	6,111	5,988	13,654	19.6	128.0

Source: Company data, I-Sec research

Table 2: Q4FY23 result review (consolidated)

(Rs mn)	Q4FY23	Q4FY22	%Chg YoY	Q3FY23	%Chg QoQ	FY23	FY22	%Chg YoY
Net Sales / Income from Operations	63,447	62,122	2.1	40,649	56.1	1,59,133	1,38,429	15.0
Total Income	64,791	63,398	2.2	41,531	56.0	1,77,344	1,53,682	15.4
Expenditure								
Change in Stock	340	268		(190)		(3,933)	(2,803)	
Consumption of Material	31,005	33,993	(8.8)	21,840	42.0	93,930	80,934	16.1
Purchase of traded goods	2,176	2,520	(13.7)	2,546	(14.5)	8,279	10,535	(21.4)
Employee Costs	5,636	5,828	(3.3)	5,723	(1.5)	23,173	21,280	8.9
Other Expenditure	7,316	5,013	45.9	2,978	145.6	15,037	10,021	50.0
Total Expenditure	46,473	47,623	(2.4)	32,897	41.3	1,36,486	1,20,273	13.5
EBITDA	18,318	15,775	16.1	8,634	112.2	40,859	33,409	22.3
EBITDA Margin (%)	28.3	24.9	13.6	20.8		23.0	21.7	
Other Income	662	639	3.5	586	12.8	2,808	2,315	21.3
Depreciation	1,140	1,061	7.4	1,061	7.5	4,288	4,011	6.9
Interest and Finance Costs	25	43	(42.1)	97	(74.7)	150	51	196.0
PBT	17,816	15,311	16.4	8,062	121.0	39,229	31,662	23.9
Tax Expense	4,152	3,846	7.9	2,032	104.3	9,826	8,118	21.0
MI and Profit from associates	156	86	82.0	105	49.0	459	458	0.3
PAT	13,820	11,551	19.6	6,135	125.3	29,862	24,002	24.4

Source: Company data, I-Sec research.

Q4FY23 concall takeaways

- **Orderbook.** BEL's orderbook is ~Rs606.90bn as on March 31, 2023 with an order inflow of Rs206.9bn in FY23. BEL expects orderbook inflow of Rs200bn in FY24 (excluding any big ticket programmes such as QRSAM).
- **Topline growth.** Topline growth guidance of 17% YoY for FY24 considering the execution cycle of the current orderbook. FY24's topline guidance is based on the commitment to customers.
- **EBITDA margin.** Management has guided for EBITDA margin of 21-23% for FY24 (including other income).
- **Order inflow.** BEL expects order inflow of ~Rs200bn. This includes: i) Akash Missile System (ground support system equipment) worth Rs40bn, ii) long term fuse requirements of Indian Army worth ~Rs45bn (spread over ten years), iii) shipbuilding contracts (on the basis of ordering already done) worth Rs50-60bn, iv) EW Shakti programme for ships worth ~Rs10bn, besides others.
- **Provisions and other expenses.** Higher other expenses in Q4FY23 mainly on account of higher liquidated damages provision due to supply-chain issues. In FY23, BEL booked Rs3.6bn LD provisions. However, the company also received Rs880mn worth of penalty waivers, pertaining to prior periods. Other expenses also rose owing to LD provisioning.
- Cash balance (including current investments) has increased to Rs80bn and receivables days are almost in line with last year (~148 days).
- **MRSAM programme.** Confirmatory trials are over. Evaluation programme is expected to complete next month.
- **Non-defence portfolio.** In FY23, defence portfolio was 87% and the remaining was non-defence. **Revenue mix for FY24:** Defence at 85%, non-defence at 15%.
- **Capacity building.** 1) Nagpur (Maharashtra), for ammunition at capex of Rs2bn; 2) Ibrahimpatnam (Telangana), for land-based EW systems (Rs3bn); 3) Nimmaluru (Andhra Pradesh), for advanced night vision equipment; 4) Hyderabad (Telangana), for super components at an investment of Rs1bn; and 5) Anantapur (Andhra Pradesh), for manufacturing and integration of big systems for defence and paramilitary segments. These facilities will be commissioned in next 2-3 years. Advance electro-optics facility in Andhra Pradesh is expected to be commissioned in CY24.
- **Capex.** BEL has been incurring capex of ~Rs5bn every year. For FY24, the company is targeting Rs7-8bn of capex owing to increased business needs.
- **UVA and anti-drone system.** BEL is working on high-end UAV platforms in partnership with DRDO. Besides, it is also working on anti-drone systems.
- **Lead integrator.** In Akash missile system for Army, BEL is the lead integrator and for Air Force, BEL is the main integrator, based on capability. For QRSAM, BEL is the lead integrator.
- **Destroyers/frigate.** Out of the total contract value of Destroyers/Frigates, typically ~30% value of equipment are supplied by BEL
- **EV tie-up, hydrogen fuel cell tie ups etc.** Has supplied one set of battery to Triton which is under evaluation. It will take time to build up momentum.
- **Electronic fuse.** BEL expects Rs4.5-Rs5bn of orders every year (already executing Rs1-1.5bn of fuse orders). The company is expanding its existing capacity to cater to the increased requirement. This is graded indigenisation product and the company has to make significant indigenisation progress in line with contract terms. Initially, indigenisation content requirement is 20-30% but it increases gradually as the contract progresses.

- Nearly 75% products are with indigenous design, of which 45-50% are done in collaboration with DRDO. Transfer of Technology (ToT) accounts for the remaining products.
- **Exports.** US\$48mn (Rs3.94bn) in FY23 (Rs3.94bn). In FY24, the company has targeted ~US\$94mn of export revenue.
- **Pay revision.** Next due in Jan 2027. Normal increment and DA increment will follow every year.
- **R&D expenditure in FY23.** Nearly 6.25% of revenue (Rs11bn) in FY23.

Maintain BUY


We maintain **BUY** on BEL with a revised TP of Rs140/share (earlier Rs125). We value the company at 25x FY25E EPS. BEL is one of the strategic DPSUs which is set to receive >Rs1,100bn of order inflow over the next 5 years in our view.

Key risks

Slower-than-expected orderbook build up and delay in execution could lead to lower revenue/margin.

Cashflow pressures can be a downside risk. We expect these pressures to moderate in medium term with ease in defence budgetary allocation. Also, lower-than-expected accretion in defence capital budget is a key risk – we believe the probability is low given the heightened external threat perception.

Price chart



Source: Bloomberg

Financial summary

Table 3: Profit and loss statement

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
Operating Income	1,53,682	1,77,344	2,07,365	2,42,406
Operating Expenses	1,20,273	1,36,486	1,61,303	1,86,693
EBITDA	33,409	40,859	46,062	55,712
% margins	21.7	23.0	22.2	23.0
Depreciation & Amortisation	4,011	4,288	5,054	5,477
Gross Interest	51	150	153	153
Other Income	2,315	2,808	3,856	4,049
Recurring PBT	31,662	39,229	44,711	54,131
Add: Extraordinary	-	-	-	-
Less: Taxes	8,118	9,826	11,206	13,563
Less: Minority Interest	-	-	63	78
Add: Share of profit from associates	458	459	263	264
Recurring Net Income	24,002	29,862	33,705	40,755

Source: Company data, I-Sec research

Table 4: Balance sheet

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
Assets				
Total Current Assets	2,33,495	3,00,477	3,17,976	3,37,525
of which cash & cash equiv.	98,317	1,53,502	1,58,364	1,64,980
Total Current Liabilities &				
Provisions	1,76,112	1,69,219	1,85,399	1,93,156
Net Current Assets	57,384	1,31,259	1,32,578	1,44,369
Investments	16,035	6,770	6,770	6,770
Strategic/Group	16,035	6,770	6,770	6,770
Other Marketable	-	-	-	-
Net Fixed Assets	26,753	29,629	29,970	29,493
Capital Work-in-Progress	10,060	8,549	10,910	11,001
Goodwill	13,321	9,486	9,486	9,486
Total Assets	1,23,552	1,85,693	1,89,713	2,01,120
Liabilities				
Borrowings	515	46,871	46,562	46,562
Deferred Tax Liability	15	29	29	29
Government Grants	-	-	-	-
Minority Interest	163	178	241	319
Equity Share Capital	2,437	7,310	7,310	7,310
Reserves & Surplus	1,20,423	1,31,307	1,35,572	1,46,901
Net Worth	1,22,859	1,38,616	1,42,882	1,54,211
Total Liabilities	1,23,552	1,85,693	1,89,713	2,01,120

Source: Company data, I-Sec research

Table 5: Cashflow statement

(Rs mn, year ending March 31)

	FY22	FY23	FY24E	FY25E
Operating Cashflow	26,733	33,447	34,856	42,148
Working Capital Changes	15,339	(20,779)	3,544	(5,176)
Capital Commitments	(5,546)	(5,905)	(7,756)	(5,091)
Free Cashflow	36,527	6,764	30,644	31,881
Investing Cashflow	(48,717)	26,908	(3,836)	(964)
Issue of Share Capital	-	-	-	-
Buyback of shares	-	-	-	-
Inc (Dec) in Borrowings	(18)	-	(309)	-
Others	(10,253)	(12,541)	(29,393)	(29,393)
Extraordinary Items	-	-	-	-
Chg. in Cash	(16,916)	27,037	4,862	6,616

Source: Company data, I-Sec research

Table 6: Key ratios

(Year ending March 31)

	FY22	FY23	FY24E	FY25E
Per Share Data (in Rs.)				
EPS(Basic Recurring)	3.3	1.4	4.6	5.6
Diluted Recurring EPS	3.3	1.4	4.6	5.6
Recurring Cash EPS	3.8	1.6	5.3	6.3
Dividend per share (DPS)	-	-	4.0	4.0
Book Value per share (BVPS)	16.8	6.3	19.5	21.1
Growth Ratios (%)				
Operating Income	8.9	15.4	16.9	16.9
EBITDA	4.1	22.3	12.7	21.0
Recurring Net Income	14.3	24.4	12.9	20.9
Valuation Ratios (x)				
P/E	33.2	80.0	23.6	19.6
P/CEPS	28.4	70.0	20.6	17.2
P/BV	6.5	17.2	5.6	5.2
EV / EBITDA	20.9	55.9	14.9	12.2
EV / FCF	19.1	337.6	22.4	21.3
Operating Ratios (%)				
Raw Material/Sales	57.7	55.4	57.6	58.2
SG&A/Sales	6.7	8.5	8.0	7.7
Other Income / PBT	7.3	7.2	8.6	7.5
Effective Tax Rate	25.6	25.0	25.1	25.1
NWC / Total Assets	0.5	0.7	0.7	0.7
Inventory Turnover	1.6	1.5	1.6	1.6
Receivable (days)	-	-	0.1	0.1
Payable (days)	127.9	113.2	105.8	95.6
Asset Turnover	1.3	1.0	1.1	1.2
Net D/E Ratio (x)	(0.8)	(0.8)	(0.8)	(0.8)
Return/Profitability Ratios (%)				
Recurring Net Income Margins	15.6	16.8	16.3	16.8
RoCE	25.7	21.2	23.6	27.0
RoNW	19.5	21.5	23.6	26.4
Dividend Pay-out Ratio	40.6	97.9	86.8	71.7
EBITDA Margins	21.7	23.0	22.2	23.0

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92, Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return*

ANALYST CERTIFICATION

IWe, Amit Dixit, PGDM, B.Tech, Mohit Lohia, CA; Prithish Urumkar: MBATech (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: **Mr. Prabodh Avadhoot** Email address: headservicequality@icicidirect.com Contact Number: 18601231122
